HD-OPM Archive

Coronary calcium (CAC) scores: what they mean and what to do next

What a coronary artery calcium scan actually measures, how to read a score of 0, a low score or a high score, why the number can rise while treatment is working, and what the group discusses doing next, from LDL lowering and exercise to follow-up imaging.

15 min read56 group posts cited50 studies discussed4 chartsEvidence through Nov 2026AI Summary of posts by Louis Nervegna and Gokhan Can
Key takeaways
  • The Agatston CAC score multiplies the area of calcium by a density factor of 1 to 4, so it is not a true calcium volume; 0 is excellent, a score over 400 suggests significant risk, and one post notes a score over 300 predicts events about as well as established disease.
  • A score of 0 means low risk, not no risk. In a Danish registry of 23,759 symptomatic patients, 54% had a CAC of zero, and about half of those with obstructive blockages were among them.
  • A rising score on treatment is not necessarily failure. Statins reduced events but did not slow CAC in trials such as SALTIRE (progression 26% on atorvastatin 80 mg vs 18% on placebo), consistent with soft plaque turning into stable calcified plaque.
  • Louis argues the target should be soft plaque, not the number, and the group's practical advice centers on LDL below 70 mg/dL, about 30 lb of weight loss where relevant, a Mediterranean-style diet and regular exercise.
  • Two 2026 randomized trials found that CAC screening did not improve outcomes for the average person, so the scan is best used to settle borderline treatment decisions.
In this summary
  1. What the score measures
  2. Turning a score into risk
  3. Understanding a score of zero
  4. Low and moderate scores
  5. Why the score can rise while treatment works
  6. Can calcium be slowed or lowered?
  7. Does getting the scan help?
  8. What this means for you
  9. Frequently asked questions
  10. The evidence behind this summary

A coronary artery calcium (CAC) scan is a quick, non-contrast CT of the heart that detects calcium in the walls of the coronary arteries. The result, usually the Agatston score, is widely used to estimate the chance of a future heart attack. A score of zero is excellent, and a score over 400 suggests significant risk1. A review shared in the group describes CAC as the most robust predictor of coronary events in people without symptoms, particularly those at intermediate risk2.

The number is easy to over-read in both directions. A zero does not mean there is no plaque, because early plaque is soft and does not show up on the scan34. A high or rising number does not necessarily mean you are getting worse, because treatment can turn dangerous soft plaque into harmless-looking calcium15. This summary explains what the score measures, how to interpret zero, low and high results, and what the group's admins suggest discussing with a doctor next.

0is excellent; over 400 suggests significant risk1
54%of 23,759 symptomatic Danish patients had a score of zero, yet they included about half of those with blockages6
10–15 yearsfor soft plaque to begin calcifying, so early disease is often invisible on the scan4
33%fewer events on atorvastatin in the St. Francis Heart Trial, even though CAC kept rising5

What the score measures

Calcified plaque is the older, hardened part of atherosclerosis. The scanner measures the area of each calcium deposit and multiplies it by a density factor of 1, 2, 3 or 4, depending on how bright the deposit looks on the image1. This is a rigid step system rather than a smooth curve, so a borderline deposit that becomes slightly denser can jump from factor 2 to 3 and raise its contribution by 50 percent even if its size barely changes1. In other words, the Agatston score is not the exact volume of calcium in your arteries.

Louis Nervegna explains why the score predicts risk at all: the amount of calcified plaque acts as a proxy for the amount of dangerous soft plaque, which develops into calcified plaque over a long period8. An ACC guidance summary he shared makes the same point from the imaging side: a CAC score reflects only calcified plaque, while CT angiography with AI quantitative plaque analysis can characterize all plaque types, including soft, low-density plaque that is more likely to rupture9.

Louis shared a chart of how CAC scores are distributed across ages10, and an article on a study proposing CAC as a simple marker of overall biological ageing, noting the scan takes seconds and often costs $100 or less11.

How common each CAC score is by age
Men: the share with a score of 0 falls steadily with age, while scores of 81–400 and over 400 become common from the 60s. From a CAC scoring guide shared by Louis.
Men: the share with a score of 0 falls steadily with age, while scores of 81–400 and over 400 become common from the 60s. From a CAC scoring guide shared by Louis.10
Women: most have a score of 0 until their 50s, and high scores remain less common than in men of the same age.
Women: most have a score of 0 until their 50s, and high scores remain less common than in men of the same age.10

Turning a score into risk

Several tools appear in the group:

  • The MESA calculator converts a CAC score plus other risk factors into a 10-year risk of heart attack or stroke212.
  • The JAMA Patient Page and JAMA Insights pieces shared by Louis say a calcium score helps estimate atherosclerotic cardiovascular risk and inform statin decisions, especially for borderline or intermediate risk people not already taking a statin1314.
  • The AHA PREVENT calculator estimates 10- and 30-year risk for ages 30 to 79 without known disease. Louis warns it will underestimate risk for people with significant atherosclerosis or a high calcium score15. A 2026 JAMA analysis found that adding CAC to PREVENT-ASCVD improved prediction only modestly in US adults 45 to 79, supporting selective use in borderline to intermediate risk. Louis adds that a very high CAC should still be treated as high risk whatever a calculator says16.
A slide Louis shared for turning a score into risk: 10-year event rates by CAC score in 14,856 patients from 5 prospective studies, from 1.1–1.7% at a score of 0 to 37.0% above 1,000 (Hecht et al., JACC Cardiovascular Imaging 2015).
A slide Louis shared for turning a score into risk: 10-year event rates by CAC score in 14,856 patients from 5 prospective studies, from 1.1–1.7% at a score of 0 to 37.0% above 1,000 (Hecht et al., JACC Cardiovascular Imaging 2015).2

What counts as "high"

Dr Michael Weintraub's view, shared by Gokhan, is that CAC above 300 is equivalent to prior ASCVD for the risk of future events, so such patients could be considered for secondary-prevention-style treatment: similar risk, similar therapies17. Louis has made a similar claim, that a score above 300 carries the same 10-year prognosis as a prior heart attack, though he gave no source18.

Understanding a score of zero

A zero is genuinely reassuring about the short term. Louis shared a primer noting that a zero is associated with very low risk of events over the following years, but that low is not none3. In MESA data relayed by Louis, over a decade a zero score "trumps" a high Lp(a), and absolute event rates stay low among people with CAC 0 even when Lp(a) is elevated1920. Louis also cites MESA findings that a CAC below 100, hsCRP below 2 mg/L and low visceral fat seemed to protect people with high Lp(a), while warning that this is observational and shows associations, not causation2122.

But the group repeatedly stresses the limits:

  • Symptomatic patients. In the Western Denmark Heart Registry, 23,759 patients with suspected coronary disease symptoms had CT angiography; 54% had a CAC of zero, and about half of those with symptomatic blockages were in that group. Soft plaque can grow without calcification, especially in younger people and women62324.
  • Timing. Louis notes that it takes 10 to 15 years for soft plaque to begin calcifying, so a 45-year-old with significant soft plaque might not show calcium until about 60, and visible calcium specks can appear even when the score is zero4.
  • Early disease. The NEJM REACT study of 16,808 adults aged 18 to 70 found plaque in 57% overall, including 8.7% of men and 6.7% of women aged 18 to 29. Among participants aged 30 to 39 with plaque on CT angiography, 41.8% of men and 48.4% of women had a calcium score of zero, and a high-risk SCORE2 category had only 1.9% sensitivity for silent disease25.
  • How common. Louis estimates roughly 10% of people with CAC 0 have significant soft plaque, and a clip he posted states that about a quarter to a third of heart attacks occur in people with a score of zero, with no study cited326.
  • Lp(a). Quoting the NLA, Louis relays that Lp(a) is not consistently associated with CAC, so a zero does not eliminate Lp(a)-related risk, particularly in younger adults. This sits alongside the MESA 10-year data above, which focused on a decade of follow-up27.
  • Cautionary example. Louis described a lean 35-year-old with CAC 0 who had a heart attack with an LDL of 372 mg/dL on a carnivore diet; it is an anecdote, not evidence28.
Plaque without calcium is common in younger adultsShare of people with plaque on CT angiography whose calcium score was zero, ages 30 to 39 (NEJM REACT study of 16,808 adults)
Men aged 30–3941.8%
Women aged 30–3948.4%
Source: 25
Show data
Value
Men aged 30–3941.8%
Women aged 30–3948.4%
An infographic of the REACT study (16,808 adults aged 18–70): plaque in any artery by age and sex, how rarely a high-risk SCORE2 category flagged it, and how often 30–39-year-olds with coronary plaque had a calcium score of zero.
An infographic of the REACT study (16,808 adults aged 18–70): plaque in any artery by age and sex, how rarely a high-risk SCORE2 category flagged it, and how often 30–39-year-olds with coronary plaque had a calcium score of zero.25

A related finding shared by Gokhan: an NEJM study of 16,000 asymptomatic people suggested plaque appears first in the neck and leg arteries in the 20s to 40s, so heart-only scans may miss early disease. He mentions carotid ultrasound (CIMT) and the ankle-brachial index as ways to look elsewhere29.

Low and moderate scores

Low and moderate scores sit on a continuum rather than falling into a single category, and the MESA analysis found that for scores of 1 to 99, high versus low Lp(a) did not change risk much, while above 100 it did1922. Treatment should still follow overall risk, with a calculator and a clinician1214.

Why the score can rise while treatment works

This is the most confusing part for people who track their scan. Gokhan's "calcification paradox" article explains that statins lower LDL and inflammation, depleting the lipid core, and the healing plaque calcifies, turning "Jell-O into concrete". The artery gets safer while the score goes up, partly because denser calcium earns a higher Agatston multiplier130. Louis called it the best article on the subject he had read30.

The trial data are consistent, though Gokhan's evidence review leans on small studies and a retrospective cohort:

  • St. Francis Heart Trial. Atorvastatin 20 mg did not reduce CAC progression over four years, yet clinical events fell by 33%5.
  • SALTIRE. Atorvastatin 80 mg lowered LDL by about 53%, but annual CAC progression was 26% versus 18% on placebo5.
  • BELLES. High and moderate intensity statins showed similar progression of about 11 to 14% in one year5.
  • Long-term cohort. In a retrospective veterans analysis, adjusted odds of severe CAC were 1.49 for 0 to 5 years of statin use, 2.38 for 5 to 10 years and 4.48 beyond 10 years, interpreted by Gokhan as ongoing plaque repair, not failure5.
  • Plaque composition. A JACC 2022 review shared by Gokhan says that on statins fibrous and calcified plaque volumes appear to increase while non-calcified, fibrofatty and necrotic core volumes decrease31. A meta-analysis of 31 IVUS studies (4,997 patients) linked LDL below 80 mg/dL and HDL above 45 mg/dL to maximal regression, with each 1% reduction in percent atheroma volume tied to 20% lower risk of major adverse cardiac events32.
The longer people took statins, the more severe calcium they hadAdjusted odds of severe CAC by years of statin use, retrospective veterans analysis
0–5 years of statin use1.49
5–10 years2.38
More than 10 years4.48
Gokhan reads this as ongoing plaque repair (soft plaque turning into calcium), not treatment failure. Observational data. Source: 5
Show data
Adjusted odds ratio (log scale)95% CI
0–5 years of statin use1.49–
5–10 years2.38–
More than 10 years4.48–

Dr Gil Carvalho's video, summarized by Gokhan, similarly says arterial calcium is a marker of long-standing plaque, not the cause of risk, so chasing a lower number can mislead33. Gerry Kurth, interviewed by Dr Ford Brewer, reported a calcium score that rose quickly at first and then stabilized and reversed after he improved lipids and carbohydrate intake, and he concluded that scores can spike in the short term even as positive changes occur34.

Can calcium be slowed or lowered?

Louis is blunt: there is typically no point trying to do anything about calcified plaque, since it usually poses little danger, and he says the focus should be on reversing or stabilizing soft plaque. He adds that removing calcium might theoretically destabilize a plaque, which is why hard-outcome trials matter more than imaging alone8. With that caveat, several approaches have been studied for slowing the number.

PCSK9 inhibitors

A 2022 randomized trial in 61 coronary patients added alirocumab 75 mg every two weeks to moderate statins; median CAC rose 2.9% versus 10.6% on statins alone over 18 months. A retrospective study by Ikegami (120 patients) found annual progression of 14.3% versus 29.7%53536. Gokhan notes the studies are small and larger trials are needed, and that Lp(a) change correlated with CAC change36. He also cites GLAGOV (evolocumab, LDL 36.6 mg/dL, percent atheroma volume -0.95% versus +0.05%) and PACMAN-AMI as examples of plaque regression without a calcification surge37.

PCSK9 inhibitors slowed calcium progression in small studiesCalcium score progression with a PCSK9 inhibitor added, versus without it
With PCSK9 inhibitorWithout
Randomized trial: alirocumab + statin vs statin alone (median, 18 months)2.9%10.6%
Ikegami retrospective study (per year)14.3%29.7%
Both studies are small (61 and 120 patients); the second is retrospective. Source: 53536
Show data
With PCSK9 inhibitorWithout
Randomized trial: alirocumab + statin vs statin alone (median, 18 months)2.9%10.6%
Ikegami retrospective study (per year)14.3%29.7%

Vitamin K2

Vitamin K2 is hypothesized to activate matrix Gla protein, which inhibits vascular calcification38. The evidence is mixed:

  • A 2023 meta-analysis of 14 RCTs (1,533 people) found a pooled difference of -17.3 Agatston units per year (95% CI -34.2 to -0.56). The largest earlier trial (389 men, 720 mcg MK-7 plus 1,000 IU vitamin D for two years) missed significance overall (+203 versus +254), but slowed progression in those with baseline CAC of 400 or more (+288 versus +380)38.
  • A 2026 JAMA Cardiology trial in adults with symptomatic coronary disease found 360 mcg/day MK-7 over two years gave a median rise of 49 versus 69 Agatston units, about 29% smaller, without removing existing calcium and without being designed to show fewer heart attacks39. Gokhan notes it mainly limited new calcification within non-calcified plaque, with no effect on stenosis or total plaque volume, and says K2 is not recommended with warfarin without checking with a doctor40.
  • Another 2026 report in 398 adults with severe calcification described 196 versus 248 points of progression (about 21% less) on 720 mcg K2 plus 1,000 IU D3, with total plaque volume rising similarly in both groups41.
  • Louis shares a summary arguing timing matters: trials in established valve calcification and in dialysis patients were null, while the trial in early coronary disease succeeded42.
  • Carvalho and Gokhan caution that no large, powered trial shows K2 reduces heart attacks or strokes, and the main danger is false reassurance and forgoing proven treatments. Gokhan adds that he takes supplements himself but expectations should stay grounded33.
Vitamin K2 slowed calcium build-up modestly in trialsIncrease in Agatston points over about two years, vitamin K2 (MK-7, some with vitamin D) versus placebo
Vitamin K2Placebo
Largest earlier trial, all 389 men (720 mcg + vitamin D)203254
Same trial, baseline CAC 400 or more288380
2026 JAMA Cardiology trial (360 mcg, median)4969
2026 report, 398 adults with severe calcification (720 mcg + D3)196248
None of these trials was designed to show fewer heart attacks, and K2 did not remove existing calcium. Source: 383941
Show data
Vitamin K2Placebo
Largest earlier trial, all 389 men (720 mcg + vitamin D)203254
Same trial, baseline CAC 400 or more288380
2026 JAMA Cardiology trial (360 mcg, median)4969
2026 report, 398 adults with severe calcification (720 mcg + D3)196248

Other approaches

Gokhan summarized three small trials of aged garlic extract (about 1.2 g/day) in which CAC progression over a year was lower than placebo, noting two used co-supplements43. Gokhan also summarized individual stories: Tom Seest's score fell from 66 to 42 over three years amid many simultaneous changes, and he admits he does not know which mattered44; Charles Grashow's score fell from 102 to 32 on high-dose statin, ezetimibe, nattokinase and other supplements, which Gokhan labels anecdotal and n=14546. These are anecdotes. Observational data point the other way for some exposures, for example a CARDIA analysis (2,226 young adults) found an animal-based low-carbohydrate diet score tied to higher CAC progression (HR 1.456), while a plant-based score was not47, and higher urinary metal levels were linked to more CAC in MESA48.

Does getting the scan help?

This is contested. In a post Louis shared, two 2026 randomized trials are cited: a Danish trial of about 30,000 men screened with CAC showed no reduction in death, heart attack or stroke at seven years and more serious bleeding, and the US CorCal trial of nearly 6,000 people found event rates identical to risk-calculator-guided care. The USPSTF does not recommend CAC for routine risk assessment in asymptomatic adults. Louis summarizes this as: for some it is a wake-up call, but for the average person it does not seem to change outcomes7. This fits the PREVENT finding that CAC adds only modestly for typical-risk people16.

The group's other posts see value in selected cases: borderline or intermediate risk people deciding on a statin1314, and following a high result with CT angiography and AI plaque analysis, which the ACC guidance suggests re-scanning at intervals of at least 2 to 5 years9. Louis recommends carotid plaque burden ultrasound, which predicted all-cause mortality better than CAC in about 5,700 people over 12.4 years (hazard ratio 1.23 versus 1.15), is cheap and uses no radiation; he says CIMT does not predict risk well495051. Gokhan, by contrast, mentions CIMT as a way to detect early peripheral plaque29. Louis also reminds members that CT scans carry radiation: CAC uses much less than CT angiography but predicts risk less accurately, and the cancer projection study was observational52.

What this means for you

  • Ask a doctor to interpret the score alongside LDL, blood pressure, glucose, family history and Lp(a), using a calculator such as MESA or PREVENT121516.
  • If your score is 0 but you are young or have symptoms or a strong risk factor, discuss whether further testing, such as CT angiography or carotid ultrasound, is warranted3625.
  • If your score is high, Louis says it is not a death sentence but does put you at high risk: his advice is about 30 lb of weight loss where relevant, LDL below 70 mg/dL through diet and medication, a traditional Mediterranean diet, and exercise, while managing all risk factors53.
  • Exercise matters at any score. Sports cardiologist Andre La Gerche is quoted as saying that for the same CAC, the fitter person has a much lower heart attack risk over 20 to 25 years; Louis adds that CAC may overestimate risk in endurance athletes545556.
  • Gokhan argues that the longer and lower LDL is held, the better, and estimates about a 60% lifetime risk reduction from a 70 mg/dL lowering sustained for 30 years, a figure read from a chart46.
  • Judge success by soft plaque and events, not only the number; if you follow plaque, consider quantitative CT angiography rather than relying on CAC89.
  • Treat supplements such as K2 as optional extras, not substitutes for proven treatment3340.

Frequently asked questions

My CAC went up on a statin. Did it fail?

Not necessarily. Statins reduced events in trials without slowing CAC, and rising calcium can reflect soft plaque stabilizing. Discuss any rise with your doctor along with your LDL and symptoms15.

Does a zero score mean I can stop worrying?

It means a low short-term risk, not zero. About half of people with symptomatic blockages in a Danish registry had a zero score, and early plaque is often non-calcified2325.

Is a score above 300 the same as having had a heart attack?

Weintraub says the risk of future events is similar to prior ASCVD, which suggests considering secondary-prevention-style treatment17.

Can vitamin K2 reverse my calcium?

Trials suggest it may slow progression, but it did not remove existing calcium, and its effect on heart attacks is unknown3940.

Should everyone get a calcium scan?

Two 2026 trials found no outcome benefit for the average person, and guidelines reportedly give it one job: informing statin decisions at borderline risk7.

The evidence behind this summary50 studies · 2 meta-analyses · 20 trials · 11 observational

The 56 group posts cited above discuss 50 studies and sources. Their mix of study designs shows how much rests on randomized trials and meta-analyses, which can show cause and effect, and how much on observational, lab or animal work, which mostly cannot.

Meta-analyses 2Randomized trials 20Observational studies 11Reviews & guidelines 8Other sources 9

Strongest evidence discussed

All 50 studies and sources
Sources from the group (56)
  1. Why a coronary calcium score can rise as plaque stabilizes on statins Gokhan Can · Dec 03, 2025 · Facebook
  2. How to convert a CAC score into a 10-year heart attack or stroke risk Louis Nervegna · Jun 01, 2024 · Facebook
  3. About 10% of people with a zero calcium score still have significant soft plaque Louis Nervegna · Nov 12, 2026 · Facebook
  4. A CAC score of zero does not rule out atherosclerosis, especially under age 45 Louis Nervegna · Jun 24, 2026 · Facebook
  5. Statins do not slow coronary calcium; severe-calcification odds hit 4.48 after 10+ years Gokhan Can · Dec 02, 2025 · Facebook
  6. A zero CAC does not rule out plaque in symptomatic patients; 54% had CAC 0 in Denmark Louis Nervegna · Dec 22, 2023 · Facebook
  7. Does a CAC scan change outcomes? Two 2026 randomized trials say not for the average person Louis Nervegna · Sep 04, 2026 · Facebook
  8. Calcified plaque is a marker, the goal should be reversing soft plaque Louis Nervegna · Aug 16, 2025 · Facebook
  9. ACC guidance backs AI plaque analysis on CT angiography to guide and track treatment Louis Nervegna · Jun 01, 2026 · Facebook
  10. Chart of CAC score distribution by age Louis Nervegna · May 16, 2024 · Facebook
  11. CAC score may be a simple measure of overall biological aging Louis Nervegna · May 18, 2024 · Facebook
  12. MESA calculator converts a CAC score into a 10-year heart attack or stroke risk Louis Nervegna · Jun 09, 2025 · Facebook
  13. JAMA Patient Page: a calcium score assesses ASCVD risk and guides statin decisions Louis Nervegna · Jun 12, 2025 · Facebook
  14. JAMA Insights: CAC score sharpens risk assessment in borderline-risk people not on statins Louis Nervegna · Apr 22, 2025 · Facebook
  15. AHA PREVENT calculator replaces Pooled Cohort Equations for ages 30-79 Louis Nervegna · Jan 25, 2024 · Facebook
  16. Adding CAC to the PREVENT risk calculator only modestly improves accuracy Louis Nervegna · Aug 26, 2026 · Facebook
  17. CAC above 300 carries risk similar to prior ASCVD and may warrant secondary prevention Gokhan Can · Jun 21, 2025 · Facebook
  18. CAC score above 300 carries a 10-year prognosis similar to a prior heart attack Louis Nervegna · Jun 09, 2025 · Facebook
  19. In MESA, high Lp(a) mattered mainly when CAC was 100 or higher Louis Nervegna · Jun 01, 2024 · Facebook
  20. High Lp(a) with a CAC score of zero still means low 10-year event risk (JACC) Louis Nervegna · May 29, 2026 · Facebook
  21. MESA: CAC under 100, hsCRP under 2 and low visceral fat may protect those with high Lp(a) Louis Nervegna · Nov 10, 2026 · Facebook
  22. MESA: high Lp(a) mostly matters when CAC is 100 or above Louis Nervegna · Jul 18, 2024 · Facebook
  23. A zero CAC score does not rule out blockages: 54% of 23,759 symptomatic patients had CAC 0 Louis Nervegna · Jan 01, 2025 · Facebook
  24. Half of people with symptomatic blockages had a CAC score of zero in Danish registry Louis Nervegna · Oct 05, 2025 · Facebook
  25. REACT: silent atherosclerosis found in 57% of 16,808 adults, 7-9% of 18-29-year-olds Louis Nervegna · Sep 26, 2026 · Facebook
  26. About a quarter to a third of heart attacks occur in people with a CAC score of 0 Louis Nervegna · Jun 07, 2024 · Facebook
  27. A CAC score of zero does not eliminate risk from high Lp(a), especially in younger adults Louis Nervegna · Apr 01, 2024 · Facebook
  28. Chiropractor had a widow-maker heart attack at 35 with CAC 0 and LDL 372 on carnivore/keto Louis Nervegna · Oct 21, 2024 · Facebook
  29. Plaque starts in neck and leg arteries decades before the heart; calcium scores miss it Gokhan Can · Sep 17, 2026 · Facebook
  30. Calcification paradox: why CAC scores can rise as the heart gets healthier on statins Louis Nervegna · May 01, 2026 · Facebook
  31. What to do with a high coronary calcium CT result: Joel Kahn's guide Gokhan Can · Nov 17, 2023 · Facebook
  32. Meta-analysis: lipid-lowering therapy regresses coronary plaque (Li 2021, SATURN) Gokhan Can · Nov 25, 2023 · Facebook
  33. Dr Carvalho: evidence for vitamin K2 supplements and arterial calcium is weak Gokhan Can · Nov 16, 2025 · Facebook
  34. Gerry Kurth's story: stent at 71, hidden glucose spikes and calcium score tracking Gokhan Can · Dec 02, 2023 · Facebook
  35. PCSK9 inhibitor plus statin nearly halted coronary calcium progression versus statin alone Gokhan Can · Dec 01, 2025 · Facebook
  36. Alirocumab plus statin slowed coronary calcium progression: +2.9% vs +10.6% at 18 months Gokhan Can · Jan 01, 2026 · Facebook
  37. PCSK9 inhibitors regress plaque without the calcification surge seen with statins Gokhan Can · Jan 01, 2026 · Facebook
  38. Vitamin K2 slows coronary calcium mainly in severe calcification; event benefit unproven Gokhan Can · Dec 02, 2025 · Facebook
  39. Vitamin K2 (MK-7) slowed coronary calcium progression in a 2-year randomized trial Louis Nervegna · Sep 08, 2026 · Facebook
  40. JAMA Cardiology trial: vitamin K2 (MK-7) for 2 years slowed coronary calcium progression Gokhan Can · Jun 10, 2026 · Facebook
  41. K2 plus D3 slowed coronary calcium progression about 21% in a 2-year trial Louis Nervegna · Sep 30, 2026 · Facebook
  42. Vitamin K2 slowed coronary calcium only when started early; two late-stage trials failed Louis Nervegna · Jun 23, 2026 · Facebook
  43. Aged garlic extract slowed coronary calcium progression in three small RCTs Gokhan Can · Nov 17, 2023 · Facebook
  44. Tom Seest's CAC drop from 66 to 42 over three years, and the debate about reversal Gokhan Can · Dec 02, 2023 · Facebook
  45. Charles Grashow's protocol to regress coronary calcium over two years Gokhan Can · Dec 02, 2023 · Facebook
  46. The longer the lower the better: lifelong LDL lowering and an estimated 60% risk reduction Gokhan Can · Nov 20, 2023 · Facebook
  47. CARDIA: low-carb diets in young adults tied to more coronary calcium if animal-based Gokhan Can · Dec 01, 2025 · Facebook
  48. Urinary metals linked to coronary calcium comparable to smoking and diabetes in MESA Gokhan Can · Sep 18, 2024 · Facebook
  49. Carotid plaque burden on ultrasound predicted mortality better than CAC in 5,700 people Louis Nervegna · Jun 30, 2025 · Facebook
  50. Ultrasound carotid plaque burden predicted mortality better than CAC over 12 years Louis Nervegna · Nov 29, 2025 · Facebook
  51. Carotid plaque burden ultrasound predicted mortality better than CAC in 5,700 people Louis Nervegna · Aug 18, 2025 · Facebook
  52. CT scan cancer risk must be weighed against the benefit of tracking plaque Louis Nervegna · Aug 21, 2025 · Facebook
  53. High CAC score is not a death sentence: weight loss, LDL below 70, diet and exercise Louis Nervegna · May 28, 2025 · Facebook
  54. With the same CAC score, fitter people have much lower heart attack risk over 20-25 years Louis Nervegna · Aug 23, 2024 · Facebook
  55. At the same CAC score, exercisers have much lower heart attack risk over 20-25 years Louis Nervegna · May 09, 2025 · Facebook
  56. For the same CAC score, fitter people have much lower heart attack risk over 20-25 years Louis Nervegna · Oct 09, 2024 · Facebook

Keep exploring

Related research summaries

Topics and hashtags in this summary